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Abstract 
 
 In the blood coagulation cascade, Factor XIII (FXIII) is a zymogen that is activated by 
thrombin (IIa) and Ca
2+
.  Activated FXIII (FXIIIa) functions as a transglutaminase in the final 
steps of the clotting cascade by forming covalent crosslinks between fibrin monomers at reactive 
glutamine residues.  This forms a stable clot structure, secure from proteolytic degradation.  To 
monitor FXIIIa substrate sequence specificity, the glutamine-containing peptide models S. 
aureus Fnb A (100-114), α2AP(Q4P) (1-15) and K9 (1-10) were introduced to the enzyme in the 
presence of 
15
NH4Cl.  Using MALDI-TOF MS and 
15
N HSQC NMR experiments, it was seen 
that α2AP(Q4P) (1-15) and K9 (1-10) were viable FXIIIa substrates, having isotopic nitrogen 
incorporated in their side chain amide groups.  However, S. aureus Fnb A (100-114) was not 
able to undergo this catalytic reaction because of an interfering side reaction with the labeled 
nitrogen.  The substrate specificity appears to be the result of chemical environment provided by 
the residues immediately surrounding the reactive glutamine, with a focus on the hybridization of 
the side chain carbons.  The αC(233-425) domain of fibrin monomers was also analyzed as an 
intact FXIIIa substrate protein.  The reactive Q
328
 residue of the protein was seen to undergo 
enzymatic transglutamination linearly with time using MALDI-TOF MS.  2D 
15
N HSQC 
experiments displayed that Q
328
 was not the only reactive glutamine in the protein but rather one 
of two or three reactive glutamines.    
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1. Introduction 
 
Hemostasis is a vital physiological process that causes the cessation of blood loss from 
wounded vessels of the circulatory system.  Without this integral response to injury, the body 
would not have the capability to quell bleeding while the vessel walls repair.  In the dynamic 
process of hemostasis, there are two basic mechanisms at work, vasoconstriction and blood 
coagulation.  The latter mechanism requires numerous enzymes working together to coordinate 
the formation of a fibrin protein clot that stops blood flow.  As seen in Figure 1, the coagulation 
pathway is described as a cascade of regulated protein activations and may be initiated in two 
possible pathways.  The extrinsic pathway comes into play in the response to injury, whereas the 
 
 
Figure 1: A schematic diagram of the 
blood coagulation cascade.  The major 
point of emphasis is on the latter steps 
which involve IIa, FXIII and 
fibrinogen.  
Intrinsic Pathway Extrinsic Pathway 
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intrinsic pathway is initiated upon appearance of blood outside of the circulatory system.  The 
two pathways later coalesce to a common enzymatic cascade that forms the fibrin clot.
1 
In the blood coagulation 
cascade, the final steps of 
clotting are achieved by 
interactions among fibrinogen 
(Fbg), thrombin (IIa) and 
Factor XIII (FXIII).  IIa is a 
serine protease that cleaves N-
terminal portions of fibrinogen 
chains, releasing 
fibrinopeptides A and B (FpA 
and FpB) and converting Fbg 
(AαBβγ)2 into fibrin (αβγ)2 monomers.  The fibrin monomers non-covalently associate into 
protofibrils and then into fibers.  This process is illustrated in Figure 2.  The flexible αC 
domains, residues 392-610, of the fibrin monomer are responsible for intermolecular interactions 
that later facilitate the strengthening of the fibrin architecture.
2  The structure of a fibrin 
monomer and its αC domain may be seen in Figure 3. As a consequence of the increase in fibrin 
concentration, the thrombin-mediated activation of FXIII is also enhanced. IIa, along with 
increased Ca
2+
 concentrations, function to activate the FXIII for the next process in the clotting 
cascade.
3 
In blood plasma, FXIII is found as a heterotetramer with an attached activation peptide.  
There are two catalytic A-subunits and two inhibitory B-subunits; however, cellular FXIII is 
found only as a dimer of two A-subunits.  IIa initially facilitates the cleavage of the activation 
 
Figure 2: Illustration of actions of IIa on fibrin monomers and the 
aggregation of fibrin protofibers.  Figure adapted from source.
2 
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peptide from the FXIII-A2, 
and then the Ca
2+
 allows 
the inhibitory FXIII-B2 to 
dissociate. The calcium
 
ions are also needed to 
bind at a Ca
2+
 binding site 
near the catalytic core for 
enzymatic activity. This 
process fully creates active 
FXIII (FXIIIa) and can be 
seen in Figure 4.  FXIIIa initially crosslinks the γ-domains of the fibrin monomers.  Then the 
enzyme can function to covalently crosslink the fibrin monomers at their αC domains, 
strengthening the clotting structure from proteolytic degradation.   
 
Cellular FXIII (FXIIIc) is found as a dimer of A subunits (FXIII-A2) and is present in the 
cytoplasm of macrophages and platelets.  FXIIIc is activated in a similar manner as FXIIIp and 
was the enzyme used in this study.
2,4
    FXIII may also be non-proteolytically activated by 
concentrations of Ca
2+ 
beyond physiological conditions, in excess of 10 mM.
5
       
 
 
Figure 3: Illustration of the structure of a fibrinogen monomer, 
including fibrinopeptides and αC domains.  Figure modified from 
source.
2 
Figure 4:  IIa and CaCl2 
activation of plasma and 
cellular FXIII.
6
  Cellular 
Plasma 
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The crosslinking of fibrin monomers is achieved by FXIIIa’s transglutaminase activity, 
which catalyzes an acyl transfer reaction between the side chain of a reactive glutamine (Q) and 
the side chain of normally a 
lysine (K) residue.
7
  The γ-
carboxyamide of the glutamine residue serves as the acyl donor while the lysine residue 
functions as the acyl acceptor.  A Q-containing substrate is initially bound in the enzyme’s 
catalytic thiol-containing site and is then followed by the nucleophilic attack of a K-containing 
substrate’s sidechain amine.  This creates the isopeptide bond between the two residues and 
releases FXIII.
7 
 A diagram of the transglutamination between glutamine and lysine may be seen 
in Figure 5. A number of physiological substrates for FXIIIa have been identified; however, a 
clear consensus sequence for the glutamine-containing substrate is not yet known.   
 
 
Figure 5:  The transglutamination 
between a glutamine and lysine 
facilitated by FXIIIa.  FXIIIa forms an 
acyl enzyme intermediate, releasing 
ammonia.  The lysine then attacks the 
intermediate and forms the isopeptide 
bond.  
 
 
Protein1 - Gln C NH2
O
+ H2N Lys - Protein 2
NH3
Protein1 - Gln Lys - Protein 2C
O
NH
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To analyze FXIIIa’s reactivity and substrate sequence specificity, varying peptide 
models, approximately ten to fifteen residues in length, can be used.  Because the exact source of 
FXIIIa’s substrate specificity is not fully understood, the peptide sequences seen in Table 1 will 
provide insight into how varying amino acid sequences affect enzymatic activity.  Each peptide 
model contains at least one reactive glutamine and has previously been shown to be an effective 
FXIIIa substrate.  Staphylococcus aureus (S. aureus) is a pathogenic bacterium that contains a 
fibronectin binding protein A (Fnb A) that is able to be crosslinked into the human fibrin 
network.  The Fnb A therefore allows the S. aureus to anchor on to its host cell.
7,8
  
 
Another 
effective FXIIIa substrate is α2-antiplasmin (α2AP), a protein that prevents the activation of 
plasmin from plasminogen. Plasmin is a protease that lyses existing clots.  α2AP contains two 
potentially reactive glutamines in residues 1-15 that target FXIIIa’s active binding site; however, 
only Q2 participates in vivo.  FXIIIa forms a crosslink between Q2 of α2AP and K303 of the 
fibrin α-chain.  An α2AP mutant, Q4P, also is used because of its substitution of the peptide’s 
second glutamine for a proline. This mutation would allow the enzymatic role of the second 
position glutamine to be probed.  The peptide K9 (1-10) is also a peptide of interest, primarily 
because it only contains one glutamine residue.  The K9 peptide  is based on the reactive site of a 
larger FXIII substrate, β-casein.
3  
 
FXIIIa’s substrate reactivity can be successfully modeled with the above mentioned sample 
peptides; however, to fully understand the scope of the enzyme’s natural function, intact proteins 
Table 1: Glutamine-Containing FXIIIa Peptide Substrates and Q-containing αC regions 
Substrate Sequence (aligned by reactive Q) 
S. aureus Fnb A (100-114) 
100
SGDQRQVDLIPKKAT
114 
α2AP (native)  (1-15) 
     1
NQEQVSPLTLLKLGN
15 
α2AP(Q4P)   (1-15) 
     1
NQEPVSPLTLLKLGN
15
 
K9  (1-10) 
1
LGPGQSKVIG
10
 
αC(325-342) 
325
TGNQNPGSPRPGSTGTWNP
342 
αC(363-382) 
363
STGQWHSESGSFRPDSPGSG
382 
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and/or protein domains must also be studied.  In previous work, it has been shown that the 
fibrinogen αC region, residues 233-425, can interact and complex with FXIIIa, linking αC 
glutamines and distant fibrinogen lysine residues.  Therefore, the αC domains are major anchors 
that hold the fibrin monomers together into a complex network.
6 
 Also, recent studies suggest 
that interactions with αC(233-425) may help promote FXIII activation.  In the 192 residue αC 
region, there are three glutamines that are potential targets of FXIII’s transglutaminase activity: 
Q
237
, Q
328
 and Q
366
.  The sequence of αC(233-425) ma14y be seen below, the glutamines in 
red.
2,3,6 
  
233
TDMPQ
237
MRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWN 
SGSSGPGSTGNRNPGSSGTGGTATWKPGSSGPGSAGSWNSGSSGTGST 
GNQ
328
NPGSPRPGSTGTWNPGSSERGSAGHWTSESSVSGSTGQ
366
WHSE 
SGSFRPDSPGSGNARPNNPDWGTFEEVSGNVSPGTRREYHTEKLVTSKGD
KELRT
425 
 
From various proteolytic digests of αC(233-425), distinct Q-containing fragments can be 
generated, which allows for the observation of each glutamine’s reactivity by mass spectroscopy 
methods.  Previous work in this area had suggested that Q
237
 is not a primary enzymatic focus, 
but the preference between Q
328
 and Q
366
 remained to be made.
9  
The sequences surrounding Q
328
 
and Q
366
 can be seen in Table 1.   
The reactive glutamines of the FXIII substrates may also be monitored by the use of the 
enzymatically labeling technique (ELT).  With ELT, isotopically labeled 
15
NH4Cl can act as a 
lysine mimic and utilize FXIIIa’s transglutaminase activity to substitute the Q-NH2 on the 
substrate with 
15
NH2.  The FXIII still promotes the creation of an acyl intermediate with the 
reactive glutamine, and without lysine, will undergo 
15
N exchange.  This provides an invaluable 
technique in determining the affinity and location of the reactive glutamine in various Q-
containing peptide sequences because the isotopically labeled residues can be readily detected by 
15
N based-nuclear magnetic resonance (NMR) spectroscopy experiments.
10 
 The ELT reaction 
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Figure 6: Enzymatic labeling of the 
γ-carboxyamide of reactive glutamine 
using a 
15
N labeled ammonium 
chloride.
11 
  
may be seen below in Figure 6.  The isotopic labeling also allows the labeled nitrogen exchange 
to be verified using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) 
mass spectroscopy.  A shift in 1 m/z  unit in the MS spectra of the FXIII-reacted peptides 
indicates an isotopic exchange, a difference between 
14
N and 
15
N.
3 
  
 
 
Another function of FXIIIa is its ability to facilitate the deamidation of a reactive glutamine 
to a glutamic acid (E) in the absence of a lysine-containing substrate or mimic.  Studies have 
shown that when the substrate and enzyme are allowed to interact in an aqueous solution either 
an isopeptide bond between two of the same peptides is produced or the aforementioned 
deamidation reaction.  The alteration of the Q to E can be monitored by a TOCSY (total 
correlation spectroscopy) NMR experiment.  By analyzing S. aureus FnbA(100-114) in solution 
when it has and has not been introduced to FXIIIa should display two distinct spectra, one 
containing a Q and one containing an E resonance pattern.  In general, the deamidation produces 
an upfield shift in the glutamine’s CαH, CβH and CγH protons’ chemical shifts.
 3  
 Monitoring the ability of FXIIIa to carry out a transglutamination in response to varying 
substrate sequences provides a better understanding of the enzyme’s substrate specificity.  This 
information would allow for a more detailed understanding of how FXIIIa forms covalent cross 
links and how to manipulate them.  Additionally, the interactions between FXIIIa and the αC 
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domains of fibrin(ogen) are of integral importance in the stabilization of the clot structure.  
Understanding the preferential glutamine interactions between the two proteins would allow for 
more control when engineering new methods of altering blood coagulation.  The ability to more 
specifically regulate the rate of formation and degradation of blood clots is a tool that would 
prove useful and advantageous in all branches of healthcare and research.      
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2. Specific Aims 
 
The first aim of this research was to examine the substrate sequence specificity of FXIIIa 
by determining the amino acid sequence that provides the greatest transglutaminase 
reactivity from S. aureus FbnA, α2AP, α2AP(Q4P) and K9 peptide models.   
a) FXIIIa’s transglutaminase activity was examined by the use of the enzymatic labeling 
technique with 
15
NH4Cl.  This allowed the glutamine amide protons of the peptide models to be 
visualized using a 
15
N
 
HSQC NMR experiment. 
b) The isotopic reaction was further verified by monitoring the FXIIIa-mediated 
15
N exchange 
via MALDI-TOF MS analysis.  A shift of 1 mass unit was detected if the transglutamination was 
successful.   
The second aim of this research was to determine the reactivity of the three glutamine 
residues in the αC region of fibrinogen towards FXIIIa. 
a) In order to better monitor the enzyme’s transglutaminase activity, a lysine mimic, glycine-
ethyl ester, was crosslinked to αC(233-425).  This was developed into a timed kinetics assay.   
b) The reacted peptide was then proteolytically digested with chymotrypsin to produce distinct 
peptide fragments that allow the Q
328
 residue’s individual activity to be monitored.  Using 
MALDI-TOF MS, the rate with which the glycine ethyl ester is covalently crosslinked could be 
observed. 
c) FXIIIa was used to cross link αC(233-425) with another lysine mimic, dansylcadaverine (DC), 
in a kinetics assay.  Because DC fluoresces under UV light, the crosslinked αC+DC was isolated 
with SDS-PAGE gel electrophoresis and verified by exposure to UV radiation.  
d)  FXIIIa’s transglutaminase activity was examined by the use of the enzymatic labeling 
technique with 
15
N-labeled 
15
NH4Cl.  This allowed the glutamine amide protons of the peptide 
models to be visualized using a 1D and 2D 
15
N
 
HSQC NMR experiment.  
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3. Experimental Procedures 
 
3.1   Peptide Substrate Model Sequences and Sources, including FXIII 
 
Peptide substrate models were synthesized and purified by New England Peptide, 
Gardner, Massachusetts.  Stock concentrations of the peptides were prepared in DI water.  Their 
individual concentrations were determined by quantitative amino acid analysis (AAA Services, 
Boring, Oregon).  The substrates analyzed include the following: S. aureus Fnb A (100-114), 
α2AP (1-15), α2AP(Q4P) (1-15) and K9 (1-10).  The peptides’ individual sequences may be seen 
in Table 2.  Human cellular FXIII (A2) was recombinantly expressed in Saccharomyces 
cerevisiea and generously provided by Dr. Paul Bishop of ZymoGenetics Inc., Seattle, 
Washington.  Stock solutions of FXIII were prepared in DI water with their concentrations 
determined using an extinction coefficient of E
1%
=14.9. 
Table 2: Glutamine-Containing FXIIIa Peptide Substrates Models 
Substrate Sequence (aligned by reactive Q) 
S. aureus Fnb A (100-114) 
100
SGDQRQVDLIPKKAT
114 
α2AP (native)  (1-15) 
     1
NQEQVSPLTLLKLGN
15 
α2AP(Q4P)   (1-15) 
     1
NQEPVSPLTLLKLGN
15
 
K9  (1-10) 
1
LGPGQSKVIG
10
 
 
3.2   Non-proteolytic Activation of FXIII and 
15
N Labeling of Peptide Substrate Models 
 
The reaction was carried out in a 20mM borate buffer solution adjusted to pH 7.  This 
buffer condition supports FXIIIa activity and does not contribute any interfering protons during 
NMR analysis. The reaction design took advantage of FXIIIa’s ability to be non-proteolytically 
activated by elevated concentrations of Ca
2+
.  400nM of FXIII A2 was combined with 50mM of 
CaCl2 in the borate buffer and allowed to incubate for approximately 15 minutes at 37°C in order 
to non-proteolytically activate the enzyme.  Afterwards, 100mM of 
15
NH4Cl was added along 
with 200μM of substrate peptide, S. aureus Fnb A (100-114), α2AP (1-15), α2AP(Q4P) (1-15) or 
K9 (1-10) in individual assays. The reaction mix was allowed to incubate for 30 minutes at room 
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temperature before being prepared for analysis.  For peptide samples in the absence of FXIIIa, 
the initial addition and incubation steps with FXIII were omitted, and the remaining components, 
borate buffer, CaCl2, 
15
NH4Cl and substrate peptides were combined.  Comparing samples with 
and without the addition of FXIII will examine if the enzymatic reaction took place with respect 
to a nonenzymatically reacted control. 
3.3   MALDI-TOF MS Analysis of 
15
N-labeled Peptide Substrate Models 
 
The masses of the peptide substrates resulting from the FXIII and non-FXIII-mediated 
reactions with 
15
NH4Cl were verified using an Applied Biosystems DE-Pro MALDI-TOF mass 
spectrometer.  The peptides were placed into UV absorbing matrix using 1.0μL aliquots of each 
reaction sample mixed with 1.0μL of α-cyano-4-hydroxycinnamic acid (αCHCA) matrix 
(5mg/mL αCHCA in a 1:1:1 ratio of 0.1% TFA, ethanol and acetonitrile).
3 
0.5μL of matrix-
sample mix were spotted in triplicate on a 100-well stainless steel MALDI plate and dried using 
a speed-vacuum.  The analysis was performed scanning the m/z range from 800 to 4000 Da with 
the instrument in positive reflector mode. 
3.4   Solution 
15
N HSQC NMR Studies  
 
The 
15
N exchange seen by the peptide substrate models and αC(233-425) in the presence 
of FXIIIa was analyzed using a 
15
N heteronuclear single quantum coherence (HSQC) NMR-
based experiment.  The short acquisition time for 1D HSQC experiments allows the reaction’s 
progress to be measured as a function of time.  The 400 μl NMR sample contained a 10% by 
volume amount of D2O.  This addition serves as an internal standard for the deuterium lock on 
the NMR.   NMR samples were loaded into Shigemi NMR tubes.  Each experiment was 
performed using an initial water suppression experiment.  The parameters for each 1D 
15
N 
HSQC experiment were nt=32, np=4096 and sw≈10,000.  The parameters for each 2D 
15
N 
HSQC experiment were nt=32, np=4096, sw=11,574, sw1=1944.3, bs=64, ni=8.   The 
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parameters for each 2D TOCSY experiment were nt=32, np=4096, sw=7022.5, sw1=7022.5, 
ni=256 and arrayed phasing.  (nt= number of transients, np= number of points, sw=sweep width, 
ni=number of increments)  NMR experiments were performed on a Varian 700MHz 
spectrometer equipped with z-axis pulse field gradients using a triple resonance probe.  All 
experiments were conducted at 25°C, with chemical shifts being referenced to the solvent, H2O. 
3.4   αC Expression, Purification  
 
The αC(233-425) protein was expressed using a glutathione-S-transferase (GST)-tagged 
recombinant αC(233-425) plasmid DNA, generously provided by Dr. Helen Philippou and Dr. 
Robert A.S. Ariëns from the University of Leeds.  The protein was expressed using an 
Escherichia coli BL21 Gold DE3 cell line in three separate 4 L cultures.  IPTG was added to 
each culture to initiate the expression of the αC protein of interest.The cultures were centrifuged, 
allowing the E. coli cells to be isolated and washed. The cells were lysed open and a cell extract 
was prepared.  A protein-based solution was isolated from the cell extract.  The αC(233-425) was 
purified by using GST-affinity chromatography on an ÄKTAprime fast protein liquid 
chromatography (FPLC) instrument.  The affinity column contains resin beads that selectively 
bind the GST, allowing the GST-protein to be isolated from the other biological compounds in 
the cell-protein solution that elute off the column.  The GST tag was removed from the αC(233-
425) with the use of a PreScission Protease digest while bound to the column, allowing the 
protein of interest to be eluted in 1x phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 10mM Na2HPO4, 2 mM KH2PO4).  The remaining cleaved GST was eluted off the column 
with elution buffer containing 50 mM Tris-HCl, 20 mM reduced glutathione, 1mM DTT at pH 
8.0.  The purification method was modeled after the GE Healthcare recommended method, 
which is where the protease and chromatography columns were purchased.
9
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3.5   αC Crosslinking with Dansylcadaverine Observed by SDS-PAGE Analysis 
 
The purity of the expressed αC(233-425)’s purity was assessed and confirmed by the use 
of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  This method was 
also used to verify that the molecular weight of αC(233-425) was within the estimated range.  
The ability of the protein to be a FXIIIa substrate was assessed by enzymatically crosslinking the 
αC protein’s reactive glutamines with a lysine mimic, dansylcadaverine (DC), which fluoresces 
under UV light.  This reaction is made possible by FXIIIa transglutaminase ability.  1.12 μM of 
FXIII, 0.010μM IIa, 5 mM CaCl2 were combined in tris-acetate buffer (100 mM tris-acetate, 150 
mM NaCl, 0.1% PEG8000, pH 7.4) and allowed to incubate for 15 minutes at 37°C to activate the 
FXIII.  Afterwards, 1.0 mM DC and 7.9 μM αC(233-425) were added which initiated the 
reaction.  Aliquots of the reaction mix were taken and quenched with a solution of 10% β-
mercaptoethanol and 2% SDS at times points of 0, 15, 30 and 45 minutes in order to monitor the 
progress of the transglutamination.  The reacted samples were then analyzed using SDS-PAGE 
under non-reducing conditions.  Samples were run on a 15% acrylamide gel, visualized under 
UV light and then stained with Coomassie Blue.  
3.6   αC Transglutamination with Glycine Ethyl Ester Assay 
 
 For this assay, the expressed αC(233-425) was enzymatically crosslinked with the lysine-
mimic, glycine ethyl ester (GEE).  As before, the reaction was quenched at defined time points to 
monitor the progression of the transglutamination.  In tris-acetate buffer, 264 nM FXIII, 8.4 U/ml 
IIa, 4mM CaCl2 and 17 mM GEE were combined and allowed to incubate for 10 minutes at 
37°C.  After the incubation period, the IIa was quenched with 164 nM PPACK, which is an 
active site inhibitor of the enzyme.  Following a brief incubation time with the PPACK, 17 μM 
of the expressed αC was added to the reaction along with an additional 7 mM of CaCl2, to bring 
the total CaCl2 concentration to 11 mM.  Due to the phosphates present in the 1x PBS the αC 
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was eluted in, additional CaCl2 was added to account for the precipitation of the Ca
2+
 and the 
phosphates.  The resulting free Ca
2+
 concentration was then approximately 4 mM.  This added 
Ca
2+
 insures the continued activity of the FXIIIa.  Reactions were quenched with a 10.6 mM 
concentration of EDTA, a calcium ion scavenger.    
3.7   αC Transglutamination with GEE Assay, Chymotrypsin Digest, and MS Analysis 
 
 After the αC(233-425)-GEE reaction samples were quenched with EDTA, they were 
proteolytically digested with chymotrypsin which selectively cleaves αC after arginine and 
lysine residues.  A chymotrypsin digest is used because the αC protein is rather large to use for 
MALDI-TOF MS analysis.  The smaller protein fragments can be more accurately detected and 
allow specific glutamines to be evaluated.  Because the digest selectively produces a Q
328
-
containing fragment, the protease allowed the reaction at this reactive glutamine
 
to be 
specifically analyzed.  Each digest took place in a volume of 13.1 μl, with 6 μl of the reaction 
mix, 6 μl of chymotrypsin buffer (100 mM tris-HCl, 10 mM CaCl2, pH 7.4) and 1.1 μl of 25 
mg/ml chymotrypsin in 1 mM HCl.  The digest was allowed to proceed for 30 minutes and was 
then followed by a quench with 6 μl of 5% TFA.  After the quench, the samples were then 
prepared for MALDI-TOF MS analysis.  Because the excess salts can interfere with MALDI-MS 
analysis, the digested samples were subjected to C18 zip tipping (Millipore) prior to being 
combined with the αCHCA matrix and plated. 
3.8   Non-proteolytic Activation of FXIII and 
15
N Labeling of αC(233-425) 
The activation was carried out in a 20mM borate buffer solution adjusted to pH 7.  FXIII 
was nonenzymatically activated with elevated Ca
2+
 concentrations in this assay. 400nM of FXIII 
was combined with 50mM of CaCl2 in the borate buffer and allowed to incubate for 
approximately 15 minutes at 37°C.  Afterwards, 100mM of 
15
NH4Cl and 10mM of additional 
CaCl2, to account for phosphates, was added along with 20μM of αC(233-425) in 1x PBS. The 
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reaction mix was allowed to incubate for 45 minutes at room temperature before being prepared 
to be analyzed.  1D and 2D 
15
N HSQC NMR experiments were conducted as with the peptide 
substrate models. 
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4. Results 
 
The substrate specificity of FXIIIa was analyzed with both peptide substrate models and the 
intact αC(233-425) domain protein.  The results from the different biochemical techniques 
offered insights into the function and specificity of this integral protein in the blood coagulation 
cascade. 
4.1   MALDI-TOF MS Analysis of FXIIIa 
15
N-exchange with Substrate Peptide Models  
 
This assay proved to be a valuable tool in evaluating the extent to which FXIIIa mediated 
the isotopic 
15
N exchange at reactive glutamine residues of varying peptide sequences.  The 
difference in 1 mass unit (m/z) between the unlabeled (
14
N) and any enzymatically reacted (
15
N) 
peptide would confirm that FXIIIa’s transglutaminase reaction had occurred.  Three different 
substrate peptides, S. aureus FnbA (100-114), α2AP(Q4P) (1-15) and K9 (1-10), were exposed to 
15
NH4 in the presence and absence of FXIIIa.  The isotopic labeling assay provided insight into 
FXIIIa’s substrate sequence preference. 
 
Figure 7:  MALDI-TOF MS spectra of 
substrate models exchanged with 
15
N in the 
presence and absence of FXIIIa.  The upper 
panel of each pair displays the nonenzymatic 
product, while the lower panels display the 
enzymatically mediated products. Molecular 
Weight: S. aureus FnbA(100-114): 1697 
g/mol; α2APQ4P(1-15): 1622 g/mol; K9(1-
10): 954.6 g/mol. 
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The results of this experiment revealed the anticipated enzymatic behavior of FXIIIa on 
α2AP(Q4P) (1-15) and K9 (1-10) substrates.  The peptides appear in the MALDI-TOF spectra as 
a cluster of peaks, or a centroid, which result from the natural isotopic abundances of the atoms 
in the peptides.   As seen in Figure 7, there is a clear shift in one peptide mass (m/z) unit when 
comparing the mass centroids with and without the addition of FXIIIa.  The interesting substrate 
in this group was the S. Aureus FnbA (100-114); it displayed no mass shift.  This absence 
suggests that the expected amide exchange at the reactive Q residue was unsuccessful in both 
catalytic and non-catalytic environments.   
4.2   
15
N HSQC NMR Analysis of FXIIIa 
15
N-exchange with Substrate Peptide Models 
 
This 
15
N HSQC NMR based approach was used to monitor FXIIIa’s transglutaminase 
activity on Q-containing substrate peptides.  The 
15
N HSQC experiment selectively detects the 
resonances of the protons on isotopically labeled nitrogens.  Therefore, if the particular 
resonances of two amide protons are detected in the experiment, it is evidence of 
15
N exchange.  
Using a range of substrate sequences, other research groups have documented that the protons of 
the 
15
N-labeled glutamine amides consistently resonate with the same chemical shifts and 
peaking patterns, 6.9 and 7.5ppm as sharp singlets.
10
  However, these chemical shifts are not 
static and do vary slightly between peptide sequences or if an intact protein such as αC is being 
analyzed.  A structure of the 
15
N-labeled glutamine may be seen in Figure 8.  
 From examining the spectra in Figure 9, it can 
be seen that FXIIIa behaviors were not consistent 
among the three different peptide sequences.  
Beginning with K9(1-10), the FXIIIa-mediated 
reaction displayed a very clear peaking pattern that 
B 
C 
A 
 
Figure 8: 
15
N-labeled glutamine at its 
amide group.  
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other research groups have previously proven indicative of the enzymatically mediated isotopic 
amide exchange.  The resonances appeared at the anticipated frequencies and rendered two 
sharp, separate peaks.
10 
 In the absence of FXIIIa, there were no resonating protons in the 
spectra, indicating that the 
15
NH4 was not exchanged at the reactive glutamine.  
  
 
Figure 9:  1D 
15
N HSQC NMR spectra for region of interest (5.5-8ppm) in FXIIIa-mediated 
15
N-exchange of 
substrate models.  All samples includes 400μM peptide, 20mM borate buffer (pH 7), 50mM CaCl2, 100mM 
15
N 
NH4Cl and varying by the addition or omission of 400nM FXIII.  Samples were 10% D2O.  
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The next two substrates rendered more interesting results.  The α2AP(Q4P) (1-15) 
displayed the correct carboxyamide protons frequencies in the FXIIIa-mediated reaction, which 
was expected.  However, in the absence of FXIIIa, there was a new weak resonance in the region 
between the observed locations of the two enzymatic peaks.  The unexpected peak suggests that 
there is a potential nonenzymatically mediated exchange between the peptide and the labeled 
ammonium. It should be noted that this unexpected peak was distinct to the reaction without 
FXIIIa and was not evident in the enzymatically reacted α2APQ4P sample’s spectrum.  The S. 
aureus FnbA(100-114) takes the unanticipated side reaction further by displaying the unknown 
resonance at approximately 7 
ppm in both the FXIIIa and non-
FXIIIa-mediated reaction.  The 
peaking pattern not only 
provides evidence of some 
unanticipated interaction, but 
also shows that this occurrence 
hinders the ability of FXIIIa to 
catalyze the reaction.  The 
unanticipated peak at 
approximately 7 ppm is the only 
peak seen in the spectrum of the 
enzymatic reaction.  Neither of 
the sharp amide singlets is 
observed, indicating that the 
 
Figure 10:  2D 
15
N HSQC NMR spectra of  α2AP(Q4P) (1-14) 
and S. aureus Fnb A (100-114) in the presence of FXIII.  
Spectra were collected as previous work of Dr. Prakash 
Doiphode. 
α2AP(Q4P) (1-14) +FXIII 
S. aureus Fnb A (100-114) +FXIII 
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expected 
15
N-glutamine exchange had not taken place.  
Previously generated 2D HSQC NMR spectra of α2AP(Q4P) (1-14) and S. aureus Fnb A 
(100-114) in the presence of FXIIIa and 
15
NH4 were reviewed
10
.  They may be seen in Figure 10.  
The results showed a positive correlation to the results of the 1D spectra in Figure 9.  The 
α2AP(Q4P) peptide spectrum shows two strong peaks that resonate at approximately 6.5 and 7.3 
ppm in the 
1
H dimension, which correlates to the chemical shifts observed in 1D resonances.  
Also, the two peaks fall in a reasonable range in the 
15
N dimension to be classified as glutamine 
side chain amide protons (110-115 ppm).  Though not giving the clean amide peaks, the S. 
aureus Fnb A peptide produced a similar peak in both 1D and 2D HSQC spectra.  The large, 
broad peak falls at the same 
1
H frequency in both 1D and 2D spectra. However, the 
15
N 
frequency resonates at approximately 130 ppm, outside of the plausible glutamine side chain 
amide range.  The 
15
N must have incorporated into the peptide in a manner other than a 
traditional transglutamination because the appearance of any resonance is indicative of 
15
N being 
bonded to the peptide.       
4.3   TOCSY NMR Analysis of FXIII Deamidation with Substrate Peptide Models  
 
 In the absence of a lysine mimic, FXIIIa can facilitate a deamidation of the reactive 
glutamine to a glutamic acid.  This chemical reaction can be monitored via a 2D TOCSY NMR 
experiment.  In order to have a base of comparison for the deamidation reactions, the chemical 
shifts of the native Q-containing peptides first had to be identified.  The TOCSY spectra of 
native S. aureus Fnb A (100-114), α2AP(Q4P) (1-15) and K9 (1-10) were collected and analyzed.  
The spectra of each peptide and assigned chemical shift table may be seen in Appendix A.  Due 
to complications in sample preparation of the FXIIIa-reacted peptides, the spectral quality was 
greatly reduced which hindered the ability to fully assign all amino acid chemical shifts. 
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Therefore, a visualization of the deamidation was not possible, but the assignment of the native 
peptide spectra provides valuable information for future work.  
4.4   SDS-PAGE Analysis of αC(233-425) Purification  
 
 The peptide substrates served as models to observe FXIIIa’s sequence specificity; 
however, αC(233-425) allowed the enzyme’s activity to be observed in the presence of an intact 
substrate protein. After being eluted as fractions off the GST-affinity column, the purity of the 
expressed αC(233-425) was assessed by the use of SDS-PAGE.  In Figure 11, the gradient 
polyacrylamide gel stained with Coomassie Blue may be seen.  The cellular protein solution 
prior to being loaded on the GST-column was run in Lane 1.  As expected, it contained 
numerous proteins based on the many bands seen in the gel.  The same observation can also be 
made of Lanes 2 and 3.  Lane 2 holds the eluent released while the protein solution was loaded 
on the column.  This eluent also contains many proteins because the only protein that is 
selectively maintained on the column is the GST-tagged αC.  Lane 3 contains the eluent from 
washing the protein-bound column with PBS in order to remove any residual, extraneous 
proteins.  This wash is why the same band pattern is observed in Lane 3 as with the preceding 
two lanes, because Lanes 1-3 all contain the same proteins, excluding αC.  Lanes 4 and 5 both 
contain separately eluted fractions of αC(233-425).  Because of the presence of only one band in 
each, this confirmed the fractions’ purities.  Also, the bands in Lanes 4 and 5 ran level with the 
molecular marker indicating 20 kDa, which is in expected mass range of the protein 
(MW=19,500 Da). 
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4.5   SDS-PAGE Analysis of αC(233-425) Crosslinking with DC 
 
The reactivity of αC(233-425) as a FXIIIa substrate was confirmed by the protein’s 
ability to be crosslinked to the lysine-mimic, dansylcadaverine (DC).  The structure of DC may 
be seen in Figure 12.  Activated via IIa and Ca
2+
,
 
FXIIIa catalytically initiated the 
transglutamination of the protein’s reactive glutamines with DC.  When exposed to UV light, the 
DC fluoresces which will allow the crosslinked αC+DC bands to be visualized.  The gel of 
crosslinked αC-DC exposed to UV light may be 
seen in Figure 13.  The band at 20 kDa can be 
seen to fluoresce, indicating that the suspected 
protein band observed in the eluted fractions was 
αC. 
 
 
 
 
 
 
Figure 11:  Gradient (4-20%) polyacrylamide gel stained with Coomassie Blue.  Lane 1: Cell 
solution before loaded on the column; Lane 2: the load eluent; Lane 3: wash eluent; Lanes 4 
and 5: collected αC(233-425) fractions.  αC(233-425) MW = 19,500 Da.  
MW 
Marker 1 2 3 4 5 
20 kDa 
50 kDa 
150 kDa 
MW 
Marker 
 
Figure 12: Structure of the lysine-mimic, 
dansylcadaverine. (DC) 
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4.6   MALDI-TOF MS Analysis of αC(233-425) Q
328
-GEE Crosslinking 
 
 To monitor the rate at which FXIIIa reacts with the targeted Q
328
 of αC(233-425), the 
protein was crosslinked with the lysine-mimic, glycine ethyl ester.  The structure of GEE may be 
seen in Figure 14.  Samples were allowed to react for discrete periods of time prior to a FXIIIa 
quench.  Glutamine 328 was selectively monitored via a chymotrypsin digest followed by 
MALDI-TOF MS analysis.  The digested fragment, αC(315-342), containing the reactive Q of 
interest, exhibited a mass of 2448 m/z.  As the reaction time was increased, the appearance of a 
new fragment for GEE (86 m/z) crosslinked with the Q-containing αC(315-342) was observed.  
From Figure 15, the MALDI-TOF MS spectra of the chymotrypsin digests at different FXIIIa 
quench times may be seen, with the field zoomed to feature the Q-containing peak and the 
GEE+Q
328
 peak.  As the reaction time increased, the intensity of the crosslinked peak grew in 
relative intensity while the Q-reactant’s peak diminished.  There were some extraneous weak 
peaks that appeared between the two peaks of interest. 
These are contaminants and not sodiated or potassiated 
peaks that need to be accounted.   
 To analyze the kinetic results in a more 
quantitative manner, the changing concentration of the 
 
Figure 13: SDS-PAGE 4-20% gradient gel displaying crosslinked αC(223-425) (7.9μM) with 
dansylcadaverine exposed to UV light.  The four αC+DC bands are faint compared to the 
marker, but are discernible. 
 
 
Figure 14: Structure of the lysine-mimic 
glycine ethyl ester (GEE). 
MW 
Marker αC(233-425)  + DC Bands 
20 kD 
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free Q
328
 peak was monitored.  The consumption of the Q-reactant was monitored in each 
spectrum by the following mathematical operation:  
                    
                                        
                          12 
The results of the MALDI-TOF MS assay with respect to consumption of reactant can be seen in 
Figure 16.  From the regression of the data, it can be seen that FXIIIa’s transglutamination of 
Q
328
 progressed in a linear fashion.  However, it is very clear that Q
328
 was not completely 
crosslinked with GEE because the free Q peak never goes away in Figure 15 and the 
concentration of reactant only decreases by approximately 30 percent in Figure 16.   
 
 
  
 
 
Figure 15: The MALDI-TOF MS spectra of the chymotrypsin digested αC(233-425) with varying times 
of FXIIIIa transglutamination with glycine ethyl ester.  Field of vision zoomed to feature the Q
328
-
containg fragment and Q
328
-fragment+GEE peaks.  αC(315-342) sequence: 
315
NSGSSGTGSTGNQNPGSPRGSTGTW
342
.  Concentration of αC in the assay was 17μM. 
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4.7   
15
N HSQC NMR Analysis of FXIII 
15
N-exchange with αC(233-425) 
 
 Due to complications in concentrating the eluted αC(233-425) fractions,  no stock protein 
solutions could be generated with a concentration greater than approximately 30 μM.  This low 
concentration of stock solutions made it more complicated to prepare NMR samples that 
contained enough αC(233-425) to be visualized in the experiment.  However, one successful 2D 
15
N HSQC NMR experiment was conducted on the protein in the presence of nonproteolytically 
activated FXIIIa and 
15
NH4.  The final protein concentration in the reaction sample was 20 μM, 
which proved to be the minimal concentration of protein that could be visualized in an 
15
N 
HSQC experiment. As in the isotopic transglutamination reactions that were conducted with the 
peptide substrate models, FXIIIa can incorporate the labeled nitrogen at the glutamine side chain 
amide so it may be visualized using 
15
N HSQC.  The resulting 2D spectrum may be seen in 
Figure 17.  The αC(233-425) protein contains three glutamines, Q
327
, Q
328
 and Q
366
, with the 
latter two being the residues of enzymatic focus.
9
  In the spectrum, two sets of glutamine chain 
amide proton peaks are observed.  A distinct pair of 
15
N-attached proton peaks may be seen at 
(112.7, 7.55 ppm) and (112.7, 6.85 ppm) in the 
15
N and 
1
H dimensions, accounting for the 
isotopic exchange at one glutamine.  Another pair of peaks was observed at approximately 112.5 
 
Figure 16: Graph displaying the consumption of the αC Q
328
-containing reactant fragment over time.  
The data is based on the MALDI-TOF MS data seen in Figure 13. 
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ppm in the 
15
N dimension; however, this peaking pattern was not as well resolved in the 
1
H 
dimension.  One of the peaks in the pair was clear at 
1
H chemical shift of 6.8 ppm, while the 
other peak was split into two separate 
1
H chemical shifts, 7.45 and 7.48 ppm.  The newer 
peaking pattern seen in the pair of peaks at 112.8 ppm in the 
15
N dimension may be related to the 
chemical environment surrounding the second reactive Q or the contribution of a third glutamine 
residue.  
 
 
  
 
Figure 17: 2D 
15
N HSQC NMR spectra of αC(233-425) 20μM  in the 
presence of 
15
NH4Cl and nonproteolytically activated FXIII. 
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5. Discussion 
 
Blood coagulation is a dynamic process that involves a cascade of enzymatic activations and 
reactions.  The final stages of the clotting cascade revolve around the interactions among 
thrombin (IIa), Factor XIII (FXIIII), calcium and fibrinogen which facilitate the ultimate 
formation of a hard clot.  IIa, a serine protease, cleaves fibrinogen into fibrin monomers and 
removes the activation peptide from the FXIII.  The increased Ca
2+
 concentration allows the 
active FXIII-A2 subunit to dissociate from the inhibitory FXIII-B2 subunit and maintains the 
enzyme’s activity during coagulation.
2
  Activated FXIII (FXIIIa) then facilitates the covalent 
crosslinking between fibrin monomers, forming a hard blood clot.  FXIIIa achieves this 
crosslinking by its enzymatic ability to crosslink fibrin glutamines with normally fibrin lysine 
residues.  The αC domains of fibrin monomers are one of the key target sites for covalent 
crosslinking by FXIIIa.  However, FXIIIa does not uniformly react with glutamines found in 
vivo. Only selected Q-containing sequences are actually targeted by FXIIIa transglutamination.
3
  
The exact consensus sequence of FXIIIa’s enzymatic activity remains unknown, but with the use 
of peptide substrate models and the αC(233-425) protein, a greater insight into the enzyme’s 
selectivity may be deduced.  
5.1   FXIIIa Interactions with Peptide Substrate Models 
To monitor FXIIIa’s specificity towards a range of Q-containing amino acid sequences, 
S. aureus Fnb A (100-114), α2AP(Q4P) (1-15) and K9 (1-10) peptide interactions with the 
enzyme were studied.  FXIIIa’s ability to exchange glutamine chain amides with 
15
NH4Cl, a 
lysine mimic, provides a valuable isotopic labeling technique.
10
  The presence or absence of an 
15
N-labeled glutamine after a FXIIIa-mediated reaction was used to evaluate the extent of 
enzymatic transglutamination.  Using 
15
N HSQC NMR and MALDI-TOF MS experiments, the 
enzymatic reaction could be monitored for each peptide substrate model. 
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 By MALDI-TOF MS analysis, the exchange of the peptides’ Q-NH2 for 
15
NH2 would 
appear as a shift of 1 m/z.  From observing the results for each peptide, it was evident that not all 
three peptides were successfully 
15
N-labeled by FXIIIa.  In Figure 7, α2AP(Q4P) (1-15) and K9 
(1-10) can be seen to display an upwards shift in 1 m/z unit in the FXIIIa-reacted spectra 
compared to unlabeled controls.  This indicates a successful transglutamination because of the 1 
m/z difference between the two isotopes of nitrogen (
14
N and 
15
N).  However, this shift in the 
MALDI-TOF MS spectrum of S. aureus Fnb A(100-114) in the presence of FXIIIa and 
15
NH4 
was not observed.  This lack of change in m/z is why the spectrum of the unlabeled control is 
identical to the spectrum of the enzymatically reacted S. aureus peptide.  Therefore, the MALDI-
TOF MS data suggest that only α2AP(Q4P) (1-15) and K9 (1-10) are capable of undergoing 
enzymatic isotopic exchange via FXIIIa, while S. aureus Fnb A(100-114) is not. 
 In the 
15
N HSQC NMR studies, the change in m/z of isotopic labeling was not the aim.  
Rather, the incorporation of an atom with spin=1/2, 
15
N, was the characteristic that was taken 
advantage of in these experiments.  In the 
15
N HSQC NMR experiment, only the proton attached 
to nitrogen-15 can resonate.  This indicates that an unlabeled protein should show no resonances 
in its HSQC spectrum, while an 
15
N-labeled glutamine would produce two peaks for each 
15
N-
attached proton.
10
   
The 1D 
15
N HSQC spectra displayed in Figure 9, revealed that a range of peaking 
patterns could be observed with the peptide substrate models.  K9(1-10) presented the expected 
outcome of the experiment.  The unlabeled control showed no peaks, while the FXIIIa-reacted 
sample showed the two sharp 
15
N-amide proton peaks as anticipated.  Similarly, α2AP(Q4P) (1-
15) showed the sharp twin peaks in the spectrum of the FXIII-reacted sample, but the unlabeled 
control spectrum was not clear like that of K9 (1-10).  In the nonenzymatically reacted sample, 
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there appeared a weak, broad peak at approximately 7 ppm, which was an unexpected result.  
This unexpected resonance in the nonenzymatically reacted α2AP(Q4P) (1-15) spectrum was 
ruled out as an artifact when a similar unknown peak appeared in both of the spectra of S. aureus 
Fnb A (110-114).  In the absence of FXIIIa, the 
15
NH4 and S. aureus Fnb A peptide produced a 
strong, broad resonance at approximately the same chemical shift of 7 ppm.  The same unknown 
peak was also seen in the spectrum of S. aureus Fnb A with the addition of FXIIIa.  The 
resonance in this spectrum is weaker than that of the one seen in the spectrum of the peptide 
control, yet the peak is still very discernible in the spectrum. 
By complementing the MALDI-TOF MS data with the results of the 
15
N HSQC NMR 
results, a more encompassing picture can be formed about the substrate specificity of FXIIIa.  
From the MALDI-TOF MS data, an answer to whether or not there was FXIIIa-facilitated 
isotopic exchange at the reactive glutamine’s amide group could be deduced.  The 
15
N HSQC 
NMR experiments also provided this data; however, NMR also allowed for the examination of 
any dynamic 
15
NH4-peptide interactions that do not result in a 1 m/z shift.  This allowed FXIIIa 
transglutaminase activity to be monitored and any enzymatically hindering processes to be 
observed as well.  
By reviewing the data in Figures 7 and 9, it can be seen that both methods agreed that the 
three examined peptide models showed varying specificity towards FXIIIa.  K9 (1-10) peptide 
was a very effective substrate model in targeting FXIIIa’s enzymatic activity.  Both NMR and 
MS data show a lack of any 
15
NH4 interactions with K9 without the presence of FXIIIa, and both 
confirm the isotopic exchange when the enzyme is present.  This was the ideal situation expected 
for any peptide that functions strongly as a FXIIIa substrate.  α2AP(Q4P) (1-15) also was a 
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successful target of FXIIIa’s activity.  The appearance of two sharp NMR peaks and the 1 m/z 
MS shift confirms α2AP(Q4P)’s ability to function as a FXIIIa substrate.   
The peptide that proved to be the least effective FXIIIa substrate was S. aureus Fnb A 
(100-114).  There was no shift observed in the centroid of the MALDI-TOF MS spectrum nor 
was there an appearance of the anticipated amide proton peaks in the HSQC spectrum.  
Additionally, the NMR spectra of S. aureus Fnb A (100-114) displayed the peptide’s ability to 
actively participate in an unknown isotopic interaction in both the presence and absence of 
FXIIIa by the appearance of a broad peak at between 6.5 and 7 ppm.  This resonance was 
unexpected because any 
15
N HSQC NMR resonance, even a weak one, indicates that a labeled 
nitrogen was incorporated into the peptide structure in some manner.  However, this isotopic 
addition must be distinct from a transglutamination for two reasons: there was no appearance of 
the two sharp glutamine amide proton peaks in the HSQC spectrum nor was there a 1 m/z shift in 
the MALDI-TOF MS spectrum.  As seen in Figure 9, the S. aureus peptide participated in the 
same nonenzymatic interaction that α2AP(Q4P) (1-15) had the propensity to do.  However, S. 
aureus Fnb A (100-114) showed a much higher affinity to participate in this unanticipated 
15
N-
exchange in the absence of the enzyme than the α2AP(Q4P) peptide.  The interaction with the 
15
NH4Cl appeared to be so favorable that it out-competed FXIIIa attempts to carry out a 
transglutamination reaction.  This suggestion is based on the appearance of the same, yet more 
diminished peak in the FXIIIa-containing S. aureus Fnb A (100-114) spectrum relative to the 
nonenzymatic sample.  Therefore, it can be seen that the unanticipated isotopic interaction 
renders the peptide unable to undergo a FXIIIa-mediated reaction. 
In order to provide further insight into the unexpected 1D HSQC peak seen between 6.5 
and 7.0 ppm, 2D 
15
N HSQC NMR was utilized.  Previously produced 2D HSQC spectra for the 
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FXIIIa-
15
NH4 reactions for both the S. aureus Fnb A and α2AP(Q4P) peptides were used to view 
the 
15
N chemical shift of the peak.
11
  The 1D HSQC spectra chemical shifts are measured in the 
1
H (ppm) dimension, while a 2D spectrum will allow resonances to be measured in both the 
1
H 
and 
15
N (ppm) dimensions.   
As seen in Figure 10, α2AP(Q4P) (1-15) displays two peaks that resonate with 
1
H 
chemical shifts in the region of 7.5-6.5 ppm, the same frequencies as the sharp peaks seen in the 
1D spectrum of the peptide in Figure 9.  The chemical shift of the peaks in the 
15
N dimension is 
also in the normal glutamine amide region, 110-115 ppm.  The spectrum of the α2AP(Q4P) 
peptide thus serves as a model 2D 
15
N HSQC spectrum of a successful FXIIIa 
15
N-labeled 
glutamine.  However, the spectrum of the S. aureus peptide displayed the same broad peak as in 
the 1D spectrum, with the same 
1
H chemical shift, approximately between 7 and 6.5 ppm.  The 
peak in the 
15
N dimension had a chemical shift of approximately 131.5 ppm.  This peak therefore 
falls well out of the plausible range of glutamine side chain nitrogen protons, again verifying that 
the isotopic interaction is distinct from the transglutamination facilitated by FXIIIa. 
  An explanation of this unanticipated peak must accommodate the experimental data that 
has been found.  The labeled nitrogen is incorporated into the S. aureus Fnb A (100-114) 
structure by NMR analysis but there is no change in mass to charge ratio in the MS spectra.  This 
information would appear indicative of the 
15
N reacting with the peptide in a novel manner that 
causes a proton to be lost while the isotope is bonded to the peptide.  A reaction with these 
results would explain why there was a signal in the 
15
N HSQC in the absence of FXIIIa and why 
there was no observed shift the centroid of the MALDI-TOF spectrum.  A potentially viable 
reaction that would explain this data would be one involving the interactions among side chains 
of the reactive glutamine (
100
SGDQRQVDLIPKKAT
114
), an arginine residue, and 
15
NH4Cl. The 
 
 
34 
 
proposed mechanism for the reaction may be seen in Figure 18. The N-terminal serine residue’s 
alcohol group could attack the δ-carbon of the glutamine side chain causing a tetrahedral 
intermediate with an oxyanion (Step A).  This unstable intermediate would allow the unlabeled, 
H-bonded NH2 to leave as the carbonyl of glutamine reforms (Step B).  The new serine-
glutamine intermediate then allows 
15
NH2 to be incorporated at the glutamine side chain (Step C).  
This portion of the reaction manages the introduction of the 
15
N, while the next step involving 
 
          
 
Figure 18: Proposed mechanism for isotopic reaction observed in 
15
N HSQC experiments.  The attacking 
serine can be function intramolecularly or as a separate peptide residue.  The general acid groups used in Steps 
C and D could be serine or aspartate groups on the peptide or neighboring peptides.  
E 
B 
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arginine would account for the loss of the proton.  Once the 
15
N is incorporated at the δ-carbon of 
glutamine, instead of reforming the amide, an amidate group could form (Step D).   This 
structure places a double bond between 
15
N and C, causing a loss of one attached proton on the 
labeled nitrogen.  This step would explain the lack of a shift in m/z in the MS spectra following 
the reaction.  The oxyanion of the amidate form of glutamine could then be stabilized by 
attacking the guanidinium carbon of the adjacent arginine (Step E).  This final step would 
stabilize the negatively charged oxygen and relieve the natural charge on the arginine group. The 
proposed structure of the product can be seen in Step F of Figure 18. 
This proposed structure would satisfy both the data that was presented in the 
15
N HSQC 
NMR and MALDI-TOF MS results.  Firstly, the labeled nitrogen in the structure could cause a 
visible resonance with 
15
N HSQC analysis.  The peaks 
15
N frequency being different from that of 
normal glutamine amides can be explained by the change in nitrogen hybridization.  In the native 
glutamine, the nitrogen is sp
3
 hybridized, while in the proposed structure the 
15
N is sp
2
 
hybridized.  This could cause the nitrogen proton peak to resonate at a higher frequency in the 
nitrogen dimension compared to glutamine chain amides, which was observed in Figure 10.  
Secondly, the linking of the glutamine and arginine residues at the glutamine chain oxygen to the 
guandinium carbon of arginine allows for the loss of a proton.  This was a critical factor in 
proposing the structure, because it must accommodate the lack of m/z shift seen in the MS data.  
Additionally, the binding of the reactive Q to arginine could explain why FXIIIa was unable to 
facilitate the anticipated transglutamination.  α2AP(Q4P) may also be able to mildly undergo this 
non enzymatic reaction in a similar fashion because of the appearance of a small broad peak at 
approximately 7.0 ppm in the absence of FXIIIa.  However, because of the absence of an 
arginine residue, the mechanism would have to be distinct from the one proposed in Figure 18.  
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A future method to verify this mechanism or provide further insight into the 
15
NH4Cl-mediated 
reaction would be to conduct a tandem MS/MS mass spectrometry experiment. This strategy 
would allow for observation of exactly which portion of the peptide has 
15
N incorporated and 
consequently which residue(s) is causing the unanticipated side reaction.   
Another FXIIIa quality that was to be taken advantage of in analyzing substrate 
specificity was the enzyme’s ability to facilitate a deamidation of a glutamine to a glutamic acid 
in the absence of a lysine mimic.  This shift from a Q to E residue in the peptide structures could 
be monitored by total correlation spectroscopy (TOCSY) NMR experiments.  This NMR 
experiment allows each proton of the amino acid chains to be assigned and monitored.  The 
deamidation reaction of FXIIIa would produce a spectrum distinct from a nonenzymatically 
reacted peptide sample, based on the appearance of Q or E resonance patterns.
3
  As in 
15
N HSQC 
NMR experiment, nonenzymatically reacted peptide samples were generated first as a basis of 
comparison.  The TOCSY spectra of the assigned amino acid residues of S. aureus Fnb A (100-
114) and α2AP(Q4P) (1-15) may be seen in Appendix A.  In order to better visualize the proton 
peaks, the pH of the samples were lowered to approximately pH 3.5.  Unfortunately, various 
concentration and pH complications arose during preparation of the FXIIIa-reacted peptide 
samples.  This resulted in spectra that displayed weak and unclear resonances.  For this assay, 
certain parameters need to be further optimized to aid in producing more resolved and useful 
spectra.  However, the native Q-containing TOCSY spectra of the S. aureus Fnb A and 
α2AP(Q4P) peptides are reported in Appendix A because this was the first time these peptide 
proton frequencies were assigned and the information can serve as a future tool in analyzing the 
deamidation ability of FXIIIa.   
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5.2   FXIIIa Interactions with αC(233-425) 
 To further evaluate the catalytic capabilities of FXIIIa, an intact substrate protein was 
analyzed.  The αC domain of fibrin monomers is the target of FXIIIa transglutamination that 
causes the covalent crosslinking of the fibrin clot.  The αC(233-425) region contains three 
glutamines with two, Q
328
 and Q
366
, being potential targets to FXIIIa’s enzymatic activity.
9
  The 
preference of FXIII to these two glutamine residues has yet to be clearly analyzed.  Insights into 
these interactions would provide a clearer view of FXIIIa’s substrate specificity.       
 The intact αC(233-425) protein was expressed and purified in multiple preparations in 
order to provide stocks for FXIIIa enzymatic analysis.  In order to verify the purity and ability of 
the protein to be crosslinked by FXIIIa, SDS-PAGE was used.  The clear, single bands seen in 
the collected αC(233-425) fractions of Figure 11 show that the GST-affinity column successfully 
isolated the protein.  Additionally, when in the presence of the fluorescent lysine-mimic 
dansylcadaverine, the αC(233-425) protein displayed FXIIIa transglutamination affinity, as seen 
in Figure 13.  The isolated αC protein bands of the SDS-PAGE gel were visualized under UV 
light, indicating that the compound was incorporated into the protein by FXIIIa.  This 
information provided evidence that the expressed protein was in fact αC(233-425), based on 
molecular weight and substrate sequence specificity towards FXIIIa. 
 The MALDI-TOF MS assay designed to observe FXIIIa’s ability to crosslink the lysine-
mimic glycine ethyl ester to Q
328
 of αC(233-425) provided information on the catalytic reaction.  
Using a chymotrypsin digest, the Q
328
-containing fragment was isolated.  From Figure 15, it can 
seen that in the MALDI-TOF MS spectra of the FXIIIa-facilitated reaction, a GEE+Q
328
-
fragment peak appeared over time.  When this information was quantified with respect to the loss 
of the Q
328
 fragment over time, a linear dependency was observed.  However, from Figure 16, it 
can be seen that the slope of the graph, i.e. reaction velocity, was not as large as would be 
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expected with an enzymatic reaction.  This observation could be a result of the low concentration 
of protein that was used in the assay.  Because of issues with concentrating αC(233-425), the 
assay had to be conducted using lower than desired concentrations of protein.  This low substrate 
concentration could have not met FXIIIa’s Km value, which would have slowed the progression 
of the enzyme’s functions.  Also, continuing work in this study would include conducting the 
assay again at various αC(233-425) concentrations in order to collect each distinct slope or 
reaction velocity.  With the reaction velocities over a range of substrate concentrations, a 
Lineweaver-Burk plot could be generated to render more enzyme kinetic data. 
Further studies based on this MALDI-TOF-based assay would also try to monitor the 
enzymatic activity at Q
366
.  A different proteolytic digest from chymotrypsin must be used in 
order to isolate a Q
366
.  This data would provide a basis of comparison between the two reactive 
glutamines.  Additionally, αC(233-425) mutants could be expressed to even further selectively 
monitor the catalytic reaction at each glutamine. The first mutant of focus would be Q237N, 
Q366N.  This new protein would only allow the Q
328
 residue to be susceptible to 
transglutamination by FXIIIa.   
 The intact αC(233-425) was also introduced to the 
15
NH4Cl in the presence of FXIIIa to 
allow the protein to be isotopically labeled.  The 
15
N is incorporated into the reactive glutamine 
side chain amide groups, allowing them to be specifically monitored using 
15
N HSQC NMR.  In 
the 2D HSQC spectrum of the enzymatic reaction seen in Figure 17, there appear to be two sets 
of glutamine amide proton peaks.  However, one of the pairs of peaks was not seen as the 
expected two, clear resonances.  One of the peaks appears as two small peaks, rather than one 
larger one.  This could potentially be explained by the Q
237
 residue, which previously was not 
seen to greatly participate in crosslinking. The two strong sets of peaks would likely be the 
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resonances of the amide protons of the reactive Q
328
 and Q
366
, with the one extra peak being 
caused by mild Q
237
 activities. Future studies would be aimed at labeling the specific glutamine 
peaks in the 
15
N HSQC spectra in order to selectively monitor the enzymatic reaction at the 
residue of interest.  Also, the αC(233-425) could be expressed with 
15
N initially incorporated into 
the structure of the glutamines’ side chain amides.  In the presence of unlabeled NH4Cl, FXIIIa 
would facilitate the removal of the isotopic nitrogen.  This reaction could be monitored using a 
similar 
15
N HSQC experiment in a time dependent fashion.     
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6. Conclusion 
 
From the experimental data, FXIIIa displayed varying substrate specificity towards the 
various model peptides.  K9 (1-10) and α2AP(Q4) (1-15) proved to be viable substrates of the 
enzymatic transglutamination reaction, with K9 showing the greatest affinity.  The S. aureus Fnb 
A (100-114) peptide favored undergoing a distinct isotopic reaction with 
15
NH4, rather than the 
anticipated FXIIIa reaction.  This newly proposed interaction between reactive glutamine and 
neighboring arginine residues of the peptide and the small lysine mimic appeared to be so 
favorable that no enzymatic activity was observed in the presence of FXIIIa.  The cause of this 
substrate sequence specificity seems to come from the residues that are directly adjacent to the 
reactive glutamine.  The S. aureus Fnb A and α2AP(Q4P) peptides both have residues containing 
sp
2
 hybridized side chain carbons in arginine and glutamate, respectively, besides the reactive 
glutamine.  This hybridization quality could allow an environment for the oxyanion of the 
amidate to be stabilized, as in the proposed mechanism.  The arginine residue of S. aureus Fnb A 
(100-114) appears to undergo this reaction with greater ease than the glutamate of α2AP(Q4P) 
(1-15), as the latter peptide functioned as a FXIIIa substrate.  In contrast, K9 (1-10) has its 
reactive glutamine flanked by glycine and serine residues, both of which only have sp
3
 
hybridized side chain carbons.  This environment appears to not favor the nonenzymatic isotopic 
exchange, allowing for greater FXIIIa activity. 
Additionally, the intact αC(233-425) protein was seen to be a target of FXIIIa’s 
transglutaminase activity.  Q
328
 was observed to react with the enzyme in a linear fashion with 
time; however, because of low protein concentrations beneath the Km value of FXIIIa, the 
maximum velocity could not be reached.   αC(233-425) was able to undergo transglutamination 
at multiple glutamine residues, two and potentially three.  This work has provided insights into 
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the function and sequence specificity of FXIIIa and therefore, further information that can 
contribute to the manipulation of the blood coagulation cascade.     
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8.  Appendix A   
  
Figure A.1:  Structure of S. aureus 
Fnb A (110-114) with labeled amino 
acids. pH 7 
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8. Appendix A   
  
Figure A.1:  Structure of S. aureus 
Fnb A (110-114) with labeled amino 
acids. 
 
Figure A.2:  2D TOCSY expansion of the aliphatic region of S. aureus FnbA (110-114) (
100
SGDQRQVDLIPKKAT
114
). 
 
Figure A.3: 2D TOCSY expansion of the fingerprint region of S. aureus Fnb A (110-114) (
100
SGDQRQVDLIPKKAT
114
). 
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Figure A.4: 2D TOCSY expansion of the amide backbone region of S. aureus Fnb A (100-114) (
100
SGDQRQVDLIPKKAT
114
). 
Chemical Shift (ppm) 
residue NH CαH CβH Others 
S100 8.357 4.424 3.859 n/a 
G101 8.552 3.955 n/a n/a 
D102 8.4 n/a 2.78, 2.669 n/a 
Q103 8.384 4.29 1.97, 2.077 γ 2.341 
R104 8.29 4.252 1.828, 1.771 γ 1.618, δ 2.992 
Q105 8.384 4.29 1.97, 2.12 γ 2.341 
V106 8.125 4.055 2.058 γ 0.8992 
D107 8.267 n/a 2.769, 2.696 n/a 
L108 8.141 4.304 1.57 δ 0.8932, 0.8048 
I109 8.033 4.414 1.838 γ .09231, 0.8704 
P110 n/a 4.36 2.264, 2.032 γ 1.965, 1.866;  δ 3.881, 3.66 
K111 8.368 4.252 1.785, 1.728 γ 1.445, δ 1.675 , ε 2.992 
K112 8.32 4.29 1.795, 1.728 γ 1.445, δ 1.675 , ε 2.992 
A113 8.068 4.256 1.182 n/a 
T114 8.46 4.377 n/a γ 1.394 
 
Table A.1:  Summary of chemical shift assignments in ppm for S. aureus Fnb A(110-114).  Experiments were 
performed at 25˚C. Samples were buffered in 20 mM borate at pH 7.0, 50 mM CaCl2, 100 mM 
15
NH4, 10% D2O.  
Peptide concentration was 200μM. 
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Figure A.5:  Structure of α2AP(Q4P) 
(1-15) with labeled amino acids. pH 7 
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Figure A.7:  2D TOCSY expansion of the fingerprint region of α2AP(Q4P) (1-14) (
1
NQEPVSPLTLLKLGN
15
). 
 
 
Figure A.6:  2D TOCSY expansion of the aliphatic region of α2AP(Q4P) (1-14) (
1
NQEPVSPLTLLKLGN
15
). 
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Figure A.8: 2D TOCSY expansion of the amide backbone region of α2AP(Q4P) (1-14) (
1
NQEPVSPLTLLKLGN
15
). 
 
Chemical Shift (ppm) 
residue NH CαH CβH Others 
N1 8.303 n/a 2.815, 2.73 n/a 
Q2 8.489 n/a 2.096, 1.893 γ 2.494 
E3 8.747 4.404 2.079, 1.978 γ 2.35 
P4 n/a 4.396 2.318, 2.091 γ 1.934; δ 3.87, 3.788 
V5 8.24 4.083 2.012 γ 0.9381 
S6 8.443 n/a 3.889 n/a 
P7 n/a 4.396 2.267, 2.012 γ 1.871; δ 3.774, 3.680 
L8 7.989 4.294 1.657, 1.564 n/a 
T9 7.914 4.193 n/a γ 1.2 
L10 7.989 4.294 1.657, 1.564 n/a 
L11 7.974 4.269 1.657, 1.564 n/a 
K12 8.151 4.277 1.834, 1.741 γ 1.414, 1.365; δ 1.805, 1.756; ε 2.965 
L13 7.957 4.269 1.657, 1.564 n/a 
G14 8.344 3.922 n/a n/a 
N15 8.285 n/a 2.815, 2.73 n/a 
Table A.2:  Summary of chemical shift assignments for α2AP(Q4P) (1-14).  Experiments were performed at 25˚C. Samples 
buffered in 20 mM borate at pH 3.5, 50 mM CaCl2, 100 mM 
15
NH4, 10% D2O.  Peptide concentration was 200μM. 
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